Precision Immunotherapy for Sepsis: ImmunoSep Trial Shows Early Organ‑Function Benefit with Targeted Anakinra or IFN‑γ
Posted inCritical Care Infectious Diseases news

Precision Immunotherapy for Sepsis: ImmunoSep Trial Shows Early Organ‑Function Benefit with Targeted Anakinra or IFN‑γ

The ImmunoSep randomized trial found that biomarker-guided immunotherapy (anakinra for macrophage activation‑like syndrome; interferon‑γ for sepsis‑induced immunoparalysis) improved organ dysfunction by day 9 versus placebo, though 28‑day mortality was unchanged. Safety signals require follow‑up.
Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results
Posted innews Oncology

Camrelizumab plus Rivoceranib Delivers Substantial Survival Gain over Sorafenib in First‑line Unresectable HCC: Final CARES‑310 Results

Final CARES-310 analysis shows camrelizumab plus rivoceranib significantly improves overall survival versus sorafenib in first-line unresectable hepatocellular carcinoma, with increased but manageable toxicity. Results support the combination as an additional frontline option, especially where other immunotherapy regimens are unavailable.
IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity
Posted inHematology-Oncology news

IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity

A phase 1, single‑arm study evaluated IL‑10–expressing anti‑CD19 CAR T cells in relapsed/refractory B‑ALL, reporting feasibility and encouraging safety signals suggesting attenuated inflammatory toxicity while preserving anti‑leukemic activity. Larger controlled studies are needed to confirm benefit and infectious risk.
Dual TIGIT/PD‑1 Blockade with Domvanalimab + Zimberelimab Plus FOLFOX Shows Promising Activity in First‑Line Advanced Gastric and GEJ Adenocarcinoma
Posted innews Oncology

Dual TIGIT/PD‑1 Blockade with Domvanalimab + Zimberelimab Plus FOLFOX Shows Promising Activity in First‑Line Advanced Gastric and GEJ Adenocarcinoma

A phase 2 arm of the EDGE‑Gastric trial reports a 59% confirmed objective response rate and median PFS 12.9 months with domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX in untreated HER2‑negative advanced gastric/GEJ/esophageal adenocarcinoma, with a manageable safety profile.
Dual TIGIT and PD‑1 Blockade with Domvanalimab + Zimberelimab plus FOLFOX Shows Promising Activity in First‑Line Advanced HER2‑Negative Gastroesophageal Adenocarcinoma
Posted innews Oncology

Dual TIGIT and PD‑1 Blockade with Domvanalimab + Zimberelimab plus FOLFOX Shows Promising Activity in First‑Line Advanced HER2‑Negative Gastroesophageal Adenocarcinoma

In a phase 2 cohort (EDGE‑Gastric A1), domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX produced a 59% ORR, median PFS 12.9 months and median OS 26.7 months in 41 previously untreated HER2‑negative gastroesophageal adenocarcinoma patients, with immune‑related AEs in 27%.
Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights
Posted innews Oncology

Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights

Pooled Phase I/IIa data (n=24) indicate intratumoural VG161 is well tolerated in advanced intrahepatic cholangiocarcinoma, elicits local and systemic immune activation (APC recruitment, CD8+ T‑cell activation, M2 macrophage depletion) and suggests clinical benefit — including signals versus historical second‑line FOLFOX — warranting randomized validation.